{ "meta": { "data_length": 1, "message": "Statements retrieved successfully", "request_url": "http://api.moalmanac.org/statements?agent_id=agent%3Aorg%3Afda&proposition_id=prop%3Avtxr%3A366", "status": "success", "status_code": 200, "timestamp_elapsed": 0.012253, "timestamp_received": "2026-09-25T00:13:41.250435+00:00Z", "timestamp_returned": "2026-09-25T00:13:41.262688+00:00Z", "trace_id": "dede6bea-f07a-4a60-9179-e5562bbf4ac6" }, "service": { "github": "https://github.com/vanallenlab/moalmanac-db", "name": "Molecular Oncology Almanac", "license": "GPL-2.0", "release": "draft", "url": "https://dev.moalmanac.org", "last_updated": "2026-08-02" }, "data": [ { "id": "stmt:fda:cyramza:0:0", "type": "Statement", "description": "The U.S. Food and Drug Administration granted approval to ramucirumab in combination with erlotinib for the first-line treatment of patients with metastatic non-small cell lung cancer with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) mutations.", "contributions": [ { "id": "ctrb:vanallenlab:2024-10-30:0", "type": "Contribution", "description": "Initial access of FDA approvals", "date": "2024-10-30", "contributor": { "id": "agent:user:vanallenlab", "type": "Agent", "agentType": "contributor", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute" } }, { "id": "ctrb:fda:2020-05-29:0", "type": "Contribution", "description": "Indication received traditional approval.", "date": "2020-05-29", "contributor": { "id": "agent:org:fda", "type": "Agent", "agentType": "organization", "name": "Food and Drug Administration", "description": "Regulatory agency that approves drugs for use in the United States." } } ], "reportedIn": [ { "id": "doc:fda:cyramza", "type": "Document", "documentType": "Regulatory approval", "name": "Cyramza (ramucirumab) [package insert]. FDA.", "title": null, "aliases": [], "description": "Eli and Lily Company. Cyramza (ramucirumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/125477s042lbl.pdf. Revised March 2022. Accessed October 30, 2024.", "urls": [ "https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/125477s042lbl.pdf", "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125477" ], "doi": null, "pmid": null, "extensions": [ { "name": "agent", "value": { "id": "agent:org:fda", "type": "Agent", "agentType": "organization", "name": "Food and Drug Administration", "description": "Regulatory agency that approves drugs for use in the United States." }, "description": "The organization that published this document." }, { "name": "company", "value": "Eli and Lily Company.", "description": "The company that manufactures the cancer drug. Only applicable to market authorization documents." }, { "name": "drug_name_brand", "value": "Cyramza", "description": "The brand name of the cancer drug, per this document. Only applicable to market authorization documents." }, { "name": "drug_name_generic", "value": "ramucirumab", "description": "The generic name of the cancer drug, per this document. Only applicable to market authorization documents." }, { "name": "first_publication_date", "value": null, "description": "The publication date for the initial version of this document." }, { "name": "identification_number", "value": 125477, "description": "Identification number used by the publishing organization." }, { "name": "publication_date", "value": "2022-03-22", "description": "The publication date for the document." }, { "name": "status", "value": "Active", "description": "Whether this document is Active or Deprecated within moalmanac-db." } ] } ], "direction": "supports", "proposition": { "id": "prop:vtxr:366", "type": "VariantTherapeuticResponseProposition", "predicate": "predictsSensitivityTo", "subjectVariant": { "type": "CategoricalVariant", "description": "Placeholder. Cat-VRS does not yet support sets of categorical variants. See the 'biomarkers' extension for biomarkers associated with this Proposition." }, "conditionQualifier": { "id": "dis:oncotree:NSCLC", "conceptType": "Disease", "name": "Non-Small Cell Lung Cancer", "mappings": [], "extensions": [ { "name": "solid_tumor", "value": true, "description": "Boolean value for if this tumor type is categorized as a solid tumor." } ], "primaryCoding": { "id": "coding:oncotree:NSCLC", "code": "NSCLC", "name": "Non-Small Cell Lung Cancer", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": [ "https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=NSCLC" ] } }, "objectTherapeutic": { "id": "txgrp:76", "membershipOperator": "AND", "therapies": [ { "id": "tx:ncit:C65530", "conceptType": "Therapy", "name": "Erlotinib", "mappings": [ { "relation": "relatedMatch", "coding": { "id": "coding:rxcui:337525", "code": "337525", "name": "erlotinib", "system": "RxNorm", "systemVersion": "20250602", "iris": [ "https://mor.nlm.nih.gov/RxNav/search?searchBy=RXCUI&searchTerm=337525" ] } }, { "relation": "relatedMatch", "coding": { "id": "coding:omop:4185613", "code": "4185613", "name": "Erlotinib", "system": "OMOP", "systemVersion": "v20250827", "iris": [ "https://athena.ohdsi.org/search-terms/terms/4185613" ] } }, { "relation": "relatedMatch", "coding": { "id": "coding:sctid:414123001", "code": "414123001", "name": "Erlotinib", "system": "SNOMED", "systemVersion": "2026-03-01", "iris": [ "https://browser.ihtsdotools.org/?perspective=full&conceptId1=414123001&edition=MAIN/2026-03-01&release=&languages=en" ] } }, { "relation": "relatedMatch", "coding": { "id": "coding:omop:1325363", "code": "1325363", "name": "erlotinib", "system": "OMOP", "systemVersion": "v20250827", "iris": [ "https://athena.ohdsi.org/search-terms/terms/1325363" ] } } ], "extensions": [ { "name": "therapy_strategy", "value": [ "EGFR inhibition" ], "description": "Associated therapeutic strategy or mechanism of action of the therapy." }, { "name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types" } ], "primaryCoding": { "id": "coding:ncit:C65530", "code": "C65530", "name": "Erlotinib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": [ "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C65530" ] } }, { "id": "tx:ncit:C70792", "conceptType": "Therapy", "name": "Ramucirumab", "mappings": [ { "relation": "relatedMatch", "coding": { "id": "coding:rxcui:1535922", "code": "1535922", "name": "ramucirumab", "system": "RxNorm", "systemVersion": "20250602", "iris": [ "https://mor.nlm.nih.gov/RxNav/search?searchBy=RXCUI&searchTerm=1535922" ] } }, { "relation": "relatedMatch", "coding": { "id": "coding:omop:45766980", "code": "45766980", "name": "Ramucirumab", "system": "OMOP", "systemVersion": "v20250827", "iris": [ "https://athena.ohdsi.org/search-terms/terms/45766980" ] } }, { "relation": "relatedMatch", "coding": { "id": "coding:sctid:704259004", "code": "704259004", "name": "Ramucirumab", "system": "SNOMED", "systemVersion": "2026-03-01", "iris": [ "https://browser.ihtsdotools.org/?perspective=full&conceptId1=704259004&edition=MAIN/2026-03-01&release=&languages=en" ] } }, { "relation": "relatedMatch", "coding": { "id": "coding:omop:44818489", "code": "44818489", "name": "ramucirumab", "system": "OMOP", "systemVersion": "v20250827", "iris": [ "https://athena.ohdsi.org/search-terms/terms/44818489" ] } } ], "extensions": [ { "name": "therapy_strategy", "value": [ "VEGF/VEGFR inhibition" ], "description": "Associated therapeutic strategy or mechanism of action of the therapy." }, { "name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types" } ], "primaryCoding": { "id": "coding:ncit:C70792", "code": "C70792", "name": "Ramucirumab", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": [ "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C70792" ] } } ] }, "extensions": [ { "name": "biomarkers", "value": [ { "id": "bmkr.criterion:10", "present": true, "subject": { "id": "bmkr:10", "type": "CategoricalVariant", "name": "EGFR Exon 19 (Deletion)", "constraints": [ { "type": "DefiningLocationConstraint", "location": { "id": "ga4gh:SL.d2mE9fs239Iqh2Rx3pBVNl0txu4dXxDT", "type": "SequenceLocation", "name": null, "aliases": [], "description": "Sequence within refseq:NP_005219.2, the protein product of the MANE Select coding transcript for EGFR (refseq:NM_005228.5), corresponding to Exon 19.", "digest": "d2mE9fs239Iqh2Rx3pBVNl0txu4dXxDT", "sequenceReference": { "id": "ga4gh:SQ.vyo55F6mA6n2LgN4cagcdRzOuh38V4mE", "type": "SequenceReference", "name": "NP_005219.2", "aliases": [ "ensembl:ENSP00000275493.2", "ga4gh:SQ.vyo55F6mA6n2LgN4cagcdRzOuh38V4mE", "refseq:NP_005219.2" ], "description": "The protein product of the MANE Select coding transcript for EGFR (refseq:NM_005228.5), corresponding to the Refseq protein accession NP_005219.2.", "moleculeType": "protein", "refgetAccession": "SQ.vyo55F6mA6n2LgN4cagcdRzOuh38V4mE", "residueAlphabet": "aa" }, "start": 728, "end": 761, "sequence": null }, "relations": [], "matchCharacteristic": { "primaryCoding": { "code": "is_within", "system": "ga4gh-gks-term:location-match" } } }, { "type": "FeatureContextConstraint", "featureContext": { "id": "gene:hgnc:3236", "conceptType": "Gene", "name": "EGFR", "primaryCoding": { "id": "coding:hgnc:3236", "code": "HGNC:3236", "system": "https://genenames.org", "iris": [ "https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3236" ] }, "mappings": [ { "relation": "exactMatch", "coding": { "id": "coding:ensembl:ensg00000146648", "code": "ENSG00000146648", "system": "https://www.ensembl.org", "iris": [ "https://www.ensembl.org/id/ENSG00000146648" ] } }, { "relation": "exactMatch", "coding": { "id": "coding:ncbi:1956", "code": "1956", "system": "https://www.ncbi.nlm.nih.gov/gene", "iris": [ "https://www.ncbi.nlm.nih.gov/gene/1956" ] } }, { "relation": "relatedMatch", "coding": { "id": "coding:refseq:NM_005228.5", "code": "NM_005228.5", "system": "https://www.ncbi.nlm.nih.gov/nuccore", "iris": [ "https://www.ncbi.nlm.nih.gov/nuccore/NM_005228.5" ] } } ] } } ], "extensions": [ { "name": "biomarker_type", "value": "Somatic variant" }, { "name": "chromosome", "value": "7" }, { "name": "start_position", "value": null }, { "name": "end_position", "value": null }, { "name": "reference_allele", "value": null }, { "name": "alternate_allele", "value": null }, { "name": "cdna_change", "value": null }, { "name": "protein_change", "value": null }, { "name": "variant_annotation", "value": "Deletion" }, { "name": "exon", "value": 19 }, { "name": "rsid", "value": null }, { "name": "hgvsg", "value": null }, { "name": "hgvsc", "value": null }, { "name": "requires_oncogenic", "value": true } ] } } ], "description": "The biomarkers associated with this Proposition, each with a `present` flag indicating if the biomarker is present (true) or absent (false). Multiple biomarkers are combined with implied AND logic." } ] }, "strength": { "id": "str:ncit:C25425", "conceptType": "Evidence", "name": "Approval", "mappings": [], "primaryCoding": { "id": "coding:ncit:C25425", "code": "C25425", "name": "Approval", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": [ "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C25425" ] } }, "extensions": [ { "name": "status", "value": "Active", "description": "Whether this Statement is Active, Superseded, or Deprecated within moalmanac-db." }, { "name": "indication", "value": { "id": "ind:fda:cyramza:0", "type": "Indication", "description": "CYRAMZA is a human vascular endothelial growth factor receptor 2 (VEGFR2) antagonist indicated in combination with erlotinib, for first-line treatment of metastatic non-small cell lung cancer with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) mutations.", "contributions": [ { "id": "ctrb:vanallenlab:2024-10-30:0", "type": "Contribution", "description": "Initial access of FDA approvals", "date": "2024-10-30", "contributor": { "id": "agent:user:vanallenlab", "type": "Agent", "agentType": "contributor", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute" } }, { "id": "ctrb:fda:2020-05-29:0", "type": "Contribution", "description": "Indication received traditional approval.", "date": "2020-05-29", "contributor": { "id": "agent:org:fda", "type": "Agent", "agentType": "organization", "name": "Food and Drug Administration", "description": "Regulatory agency that approves drugs for use in the United States." } } ], "reportedIn": [ { "id": "doc:fda:cyramza", "type": "Document", "documentType": "Regulatory approval", "name": "Cyramza (ramucirumab) [package insert]. FDA.", "title": null, "aliases": [], "description": "Eli and Lily Company. Cyramza (ramucirumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/125477s042lbl.pdf. Revised March 2022. Accessed October 30, 2024.", "urls": [ "https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/125477s042lbl.pdf", "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125477" ], "doi": null, "pmid": null, "extensions": [ { "name": "agent", "value": { "id": "agent:org:fda", "type": "Agent", "agentType": "organization", "name": "Food and Drug Administration", "description": "Regulatory agency that approves drugs for use in the United States." }, "description": "The organization that published this document." }, { "name": "company", "value": "Eli and Lily Company.", "description": "The company that manufactures the cancer drug. Only applicable to market authorization documents." }, { "name": "drug_name_brand", "value": "Cyramza", "description": "The brand name of the cancer drug, per this document. Only applicable to market authorization documents." }, { "name": "drug_name_generic", "value": "ramucirumab", "description": "The generic name of the cancer drug, per this document. Only applicable to market authorization documents." }, { "name": "first_publication_date", "value": null, "description": "The publication date for the initial version of this document." }, { "name": "identification_number", "value": 125477, "description": "Identification number used by the publishing organization." }, { "name": "publication_date", "value": "2022-03-22", "description": "The publication date for the document." }, { "name": "status", "value": "Active", "description": "Whether this document is Active or Deprecated within moalmanac-db." } ] } ], "extensions": [ { "name": "status", "value": "Approved", "description": "Current approval status." } ] }, "description": "The underlying Indication supporting this Statement." } ] } ] }